Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Terns Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates - Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 in NASH, with TERN-501 meeting all primary and secondary endpoints - TERN-701 Phase 1 clinical trial for CML on track to initiate in second half of 2023; enrollment progress from ongoing China Phase 1 clinical trial presented at 2023 ASCO Annual Meeting - TERN-601 program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting; on track to initiate Phase 1 clinical trial in second half of 2023 - Cash, cash equivalents and marketable securities of $286 million expected to provide runway into 2026 FOSTER CITY, Calif., August 8, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopha..."
05/15/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates - Top-line data from Phase 2a DUET clinical trial of TERN-501 in NASH expected in third quarter of 2023 - TERN-701 Phase 1 trial for CML on track to initiate in the U.S. in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at the 2023 ASCO Annual Meeting - TERN-601 program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024 - Cash, cash equivalents and marketable securities of $298 million expected to provide runway into 2026 FOSTER CITY, Calif., May 15, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product ca..."
03/27/2023 8-K Quarterly results
11/09/2022 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights • Terns plans to initiate U.S. clinical trial for TERN-701 in CML in second half of 2023 • Positive data from Phase 1 trial of TERN-501 in NASH presented at AASLD 2022, with top-line data from Phase 2a DUET trial expected in second half of 2023 • IND-enabling activities for TERN-601 remain on track with plans to initiate first-in-human clinical trial in obesity in 2023 • Cash and equivalents of $187 million provides runway into 2025, including three clinical data readouts from Terns’ three lead programs: TERN-701, TERN-601 and TERN-501 FOSTER CITY, Calif., Nov. 9, 2022 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of sm..."
08/08/2022 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights • TERN-701 advances into Phase 1 trial for CML in China • IND-enabling activities for TERN-601 remain on track; Phase 1 obesity trial initiation expected in 2023 • Initiated dosing of TERN-501 Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023 • Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indications FOSTER CITY, Calif., August 8, 2022 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesi..."
05/16/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights -Top-line data readout from TERN-201 clinical trial in NASH expected in March 2022 -Initiation of Terns’ first NASH trial of TERN-501 alone and in combination with TERN-101 planned for first half of 2022 with top-line data expected in second half of 2023 -Nominated TERN-601 development candidate with the goal of initiating a first-in-human clinical trial in 2023 -Cash and equivalents of $166 million provides runway into 2024"
08/16/2021 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights -Top-line data from ongoing Phase 1 proof of concept clinical trial of TERN-501 expected in 4Q 2021 -Top-line data readout from Part 1 of ongoing AVIATION Trial of TERN-201 expected in 1H 2022 -Cash and equivalents of $185.1 million provides runway into 2024"
05/13/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy